Compugen (CGEN) Aandelenoverzicht
Compugen Ltd., een therapeutisch ontdekkings- en ontwikkelingsbedrijf in een klinische fase, houdt zich bezig met onderzoek, ontwikkeling en commercialisering van therapeutica en productkandidaten in Israël, de Verenigde Staten en Europa. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 4/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
CGEN Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Compugen Ltd. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$2.02 |
| 52 Week Hoogtepunt | US$3.24 |
| 52 Week Laag | US$1.30 |
| Bèta | 2.74 |
| 1 maand verandering | -23.77% |
| 3 maanden verandering | -0.98% |
| 1 Jaar Verandering | 23.93% |
| 3 jaar verandering | 80.36% |
| 5 jaar verandering | -74.75% |
| Verandering sinds IPO | -81.84% |
Recent nieuws en updates
Narratiefupdate • Jun 17
CGEN: Bullish Views Persist As Immuno Oncology Pipeline Progress Supports Upside
Analysts have reduced their price target on Compugen stock to $5, down $8 from the prior $13 target, citing updated assumptions for discount rate, profit margin and future P/E, while maintaining a constructive fundamental view on the company. Analyst Commentary Recent research on Compugen stock reflects a mix of constructive views on the company and more cautious adjustments to valuation, giving you a clearer sense of how professionals are framing risk and reward.Narratiefupdate • Jun 02
CGEN: Bullish Initiation And Pipeline Execution Will Drive Future Upside
Analysts have reduced their fair value estimate for Compugen from $6.25 to $4.60, citing lower revenue growth expectations, a modestly higher discount rate, and updated long term profitability and P/E assumptions following recent price target cuts and a new bullish initiation on the stock. Analyst Commentary Recent Street research on Compugen reflects a split view, with some analysts maintaining a constructive stance while others are resetting expectations and price targets.Seeking Alpha • May 19
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
Summary Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 studies, with strong phase 1b/2 data in HER2+ gastric cancer [70% cORR]. New data from DESTINY-Gastric03 will be presented at ASCO 2026, and interim analysis for COM701 in ovarian cancer is expected Q1 2027. CGEN has a cash runway into 2029, with $134.9M on hand and potential for $1B in milestone payments from AstraZeneca and Gilead partnerships. Read the full article on Seeking AlphaRecent updates
Narratiefupdate • Jun 17
CGEN: Bullish Views Persist As Immuno Oncology Pipeline Progress Supports Upside
Analysts have reduced their price target on Compugen stock to $5, down $8 from the prior $13 target, citing updated assumptions for discount rate, profit margin and future P/E, while maintaining a constructive fundamental view on the company. Analyst Commentary Recent research on Compugen stock reflects a mix of constructive views on the company and more cautious adjustments to valuation, giving you a clearer sense of how professionals are framing risk and reward.Narratiefupdate • Jun 02
CGEN: Bullish Initiation And Pipeline Execution Will Drive Future Upside
Analysts have reduced their fair value estimate for Compugen from $6.25 to $4.60, citing lower revenue growth expectations, a modestly higher discount rate, and updated long term profitability and P/E assumptions following recent price target cuts and a new bullish initiation on the stock. Analyst Commentary Recent Street research on Compugen reflects a split view, with some analysts maintaining a constructive stance while others are resetting expectations and price targets.Seeking Alpha • May 19
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
Summary Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming catalysts in oncology. Rilvegostomig, partnered with AstraZeneca, is being evaluated in 11 phase 3 studies, with strong phase 1b/2 data in HER2+ gastric cancer [70% cORR]. New data from DESTINY-Gastric03 will be presented at ASCO 2026, and interim analysis for COM701 in ovarian cancer is expected Q1 2027. CGEN has a cash runway into 2029, with $134.9M on hand and potential for $1B in milestone payments from AstraZeneca and Gilead partnerships. Read the full article on Seeking Alpha
Narratiefupdate • May 03
CGEN: Future Upside Will Rely On Sustained Long Term Execution Confidence
Analysts have maintained their $13.00 price target on Compugen, citing recent bullish initiation and supportive research as reasons to keep their outlook. This remains the case despite slight adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E.Narratiefupdate • Apr 07
CGEN: Future Upside Will Depend On Sustained Long Term Earnings Potential
Analysts maintained their target for Compugen at $13.00, citing updated assumptions that now reflect a slightly higher discount rate, a modestly weaker revenue growth outlook, a small reduction in expected profit margin, and a very large projected future P/E multiple. Valuation Changes Fair Value: Target remains at $13.00, with no change from the prior estimate.Narratiefupdate • Mar 22
CGEN: Unchanged US$13 Fair Value Will Rely On Long Term Earnings
Analysts kept their $13.00 price target for Compugen unchanged, with only small tweaks to underlying inputs such as discount rate, revenue growth assumptions, profit margin, and very large future P/E expectations supporting the decision to maintain the prior valuation view. Valuation Changes Fair Value: $13.00 fair value is unchanged, signaling no revision to the overall price target level.Narratiefupdate • Mar 06
CGEN: Royalty Monetization And Immuno Oncology Pipeline Will Drive Future Upside
Analysts have reiterated a $13.00 price target on Compugen, citing updated assumptions that include a slightly higher discount rate, a shift to an 11% revenue contraction, a lower profit margin near 12%, and a very large forward P/E estimate as the basis for their current stance. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, amending their 2018 exclusive license agreement to support Compugen's balance sheet and immuno oncology pipeline (Key Developments).
Nieuw narratief • Mar 03
Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story
Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Feb 20
CGEN: Royalty Sale And Oncology Pipeline Will Support Future Upside
Analysts have kept their price target for Compugen steady at $13.00, citing relatively unchanged fair value assumptions alongside small tweaks to the discount rate, very large projected revenue growth and expected profit margins, as well as an updated future P/E estimate. What's in the News Compugen and MedImmune Limited, part of the AstraZeneca Group, signed Amendment Number 4 to their March 30, 2018 license agreement covering rilvegostomig, updating the economic terms of Compugen's royalty interest (Key Developments).Narratiefupdate • Feb 06
CGEN: Royalty Monetization And Oncology Pipeline Will Drive Future Upside
Narrative Update on Compugen Analysts have kept their price target for Compugen steady at $13.00, citing only minor tweaks to assumptions around discount rate, very high projected revenue growth and profit margin that did not materially change their overall view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).Narratiefupdate • Jan 23
CGEN: Future Upside Will Be Driven By Royalty Monetization Deal
Analysts have kept their fair value estimate for Compugen steady at $13.00, with only minor model tweaks to discount rates, revenue growth assumptions and future P/E, helping to refine rather than reset their overall price target view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from the cancer drug candidate rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).Narratiefupdate • Jan 09
CGEN: Future Upside Will Be Driven By Expanded Immuno Oncology Partnerships
Analysts have maintained their price target for Compugen at $13.00. They cite updated assumptions for discount rates, revenue growth, profit margins and a very large future P/E multiple as the main factors supporting this unchanged view.Narratiefupdate • Dec 14
CGEN: Future Revenue Trajectory Will Be Driven By Ongoing COM701 Program
Analysts have raised their price target on Compugen to 13.00 dollars from 13.00 dollars, citing sharply higher projected revenue growth, improved long term profit margins and a more favorable future earnings multiple, even after incorporating a slightly higher discount rate. What's in the News Pooled analysis of COM701 Phase 1 trials in 60 evaluable patients with platinum resistant ovarian cancer published as an abstract by the European Society of Medical Oncology, highlighting anti tumor activity and safety in heavily pre treated patients (ESMO abstract) Analysis details outcomes for patients deriving clinical benefit, including progression free survival data, and is based on data from prior COM701 studies in platinum resistant ovarian cancer (Company announcement) Additional year of follow up data on COM701 in platinum resistant ovarian cancer will be featured in an upcoming ESMO poster, expanding on the initial pooled findings (ESMO poster) Compugen estimates interim analysis results for the ongoing COM701 program to be available by year end 2026, guided by the anticipated enrollment rate (Company guidance) Valuation Changes Fair Value: Unchanged at 13.00 dollars per share, reflecting no revision to the base case price target.Analyseartikel • Oct 07
There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise
Compugen Ltd. ( NASDAQ:CGEN ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Analyseartikel • Oct 02
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Narratiefupdate • Aug 08
AI And Immunotherapy Advances Will Define Oncology's Future
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.Analyseartikel • May 25
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically
One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...Analyseartikel • Apr 09
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Compugen fair value estimate is US$1.77 Current share price of...Analyseartikel • Feb 26
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
Nieuw narratief • Jan 26
COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain
Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.Analyseartikel • Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.1x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...Analyseartikel • May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. The results were...Analyseartikel • May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
Compugen Ltd. ( NASDAQ:CGEN ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Key Insights Compugen's estimated fair value is US$3.61 based on 2 Stage Free Cash Flow to Equity Compugen's US$2.32...Analyseartikel • Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Compugen Ltd. ( NASDAQ:CGEN ) shares have been powering on, with a gain of 26% in the...Analyseartikel • Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...Analyseartikel • Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyseartikel • Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyseartikel • Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...Analyseartikel • Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 12
Compugen appoints Alberto Sessa as CFO
Clinical-stage cancer immunotherapy company Compugen (NASDAQ:CGEN) on Monday said it had appointed Alberto Sessa as its CFO. The appointment follows the departure of previous CFO Ari Krashin in May. Sessa will join CGEN on Nov. 1, 2022, the company said. According to CGEN, Sessa has more than 30 years of industry experience and most recently served as acting CFO at several startups in the high-tech industry. CGEN stock flat in mid-day trading.Seeking Alpha • Aug 24
Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Compugen (NASDAQ:CGEN) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies. The Japanese patent No. 2017-562952 is expected to expire not before 2036. The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. CGEN +1.57% to $1.29 premarket Aug. 24Seeking Alpha • Aug 03
Compugen Q2 2022 Earnings Preview
Compugen (NASDAQ:CGEN) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward.Analyseartikel • Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rendement voor aandeelhouders
| CGEN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 0.5% | 5.1% | -2.7% |
| 1Y | 23.9% | 36.7% | 18.6% |
Rendement versus industrie: CGEN presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 36.7 % opleverde.
Rendement versus markt: CGEN overtrof de US markt, die het afgelopen jaar een rendement opleverde van 18.6 %.
Prijsvolatiliteit
| CGEN volatility | |
|---|---|
| CGEN Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: CGEN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van CGEN is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1993 | 75 | Eran Ophir | cgen.com |
Compugen Ltd., een therapeutisch ontdekkings- en ontwikkelingsbedrijf in een klinische fase, houdt zich bezig met onderzoek, ontwikkeling en commercialisering van therapeutica en productkandidaten in Israël, de Verenigde Staten en Europa. De pijplijn van het bedrijf bestaat uit COM701, een immuno-oncologisch pijplijnprogramma met een anti-PVRIG antilichaam; COM902, een therapeutisch anti-TIGIT antilichaam, bevinden zich in Fase 1 klinische studies en zijn geëvalueerd voor de behandeling van solide tumoren als monotherapie en in combinatie met PVRIG/PD-1 en PVRIG/TIGIT, evenals PVRIG/PD-1/TIGIT blokkade; Bapotulimab, een therapeutisch antilichaam gericht tegen ILDR2 dat wordt geëvalueerd in Fase I klinische studies bij patiënten met naïef hoofd-hals plaveiselcelcarcinoom; en Rilvegostomig, een nieuw anti-PD-1/TIGIT bispecifiek antilichaam, dat wordt onderzocht in Fase III klinische studie bij patiënten met gevorderde of gemetastaseerde niet-kleincellige longkanker. De preklinische therapeutische pijplijn omvat ook vroege fase immuno-oncologische programma's gericht op het aanpakken van verschillende mechanismen van immuunresistentie; en COM503, een antilichaam met hoge affiniteit dat de interactie tussen IL-18 bindend eiwit en IL-18 blokkeert.
Compugen Ltd. Samenvatting
| CGEN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$190.12m |
| Inkomsten(TTM) | US$34.86m |
| Inkomsten(TTM) | US$72.66m |
5.5x
Koers/Winstverhouding2.6x
P/S-verhoudingIs CGEN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CGEN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$72.66m |
| Kosten van inkomsten | US$8.68m |
| Brutowinst | US$63.98m |
| Overige uitgaven | US$29.13m |
| Inkomsten | US$34.86m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.37 |
| Brutomarge | 88.06% |
| Nettowinstmarge | 47.97% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde CGEN op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/25 16:02 |
| Aandelenkoers aan het einde van de dag | 2026/06/25 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Compugen Ltd. wordt gevolgd door 10 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |